d06

AL 082D06 (D-06), a selective nonsteroidal glucocorticoid receptor (GR) antagonist (Ki: 210 nM), exhibits outstanding selectivity against AR, ER, MR and PR(Ki > 10 uM).

(S)-WSD0628 is the S isomer of WSD0628 and serves as an ATM inhibitor, effectively suppressing ATM phosphorylation in MCF-7 cells with an IC50 of less than 100 nM. This compound also demonstrates radiosensitizing activity and is capable of penetrating the blood-brain barrier.

CYD0682 is an analog of Oridonin. It reduces the activation of STAT3 and the production of ECM in hepatic stellate cells via the HSP90 pathway.

WSD0628 is a brain-penetrant and potent ATM inhibitor with a significant radiosensitizing effect [1].

BRD0639 is a pioneering inhibitor targeting the interaction between PRMT5 and its substrate adaptor. As a competitive inhibitor of the PRMT5 binding motif (PBM), BRD0639 facilitates the investigation of activities dependent on PBM-associated PRMT5 functions [1].

PVD-06 is a selective PROTAC-based degrader of PTPN2 (with a selectivity index of greater than 60-fold over PTP1B) and exhibits anticancer activity. It induces the degradation of PTPN2 through ubiquitination and proteasome-dependent pathways. PVD-06 also enhances T cell activation and amplifies IFN-γ-mediated cytotoxicity.

VVD 065 is an NRF2 inhibitor that functions through a covalent allosteric binding mechanism. It promotes the degradation of NRF2 by covalently bonding with C151 on KEAP1, thereby enhancing the formation of the KEAP1-CUL3 ubiquitin ligase complex. With potent target binding affinity (TE50 of 9 nM in KYSE70 cells) and selectivity for unrelated targets, VVD 065 effectively inhibits NRF2-associated cell growth.

Elvitegravir (JTK-303) is a Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor. The mechanism of action of elvitegravir is as an HIV Integrase Inhibitor, and Cytochrome P450 2C9 Inducer.

Zosuquidar trihydrochloride (LY-335979 trihydrochloride) is a potent modulator of P-glycoprotein-mediated multi-drug resistance with Ki of 60 nM. Phase 3.

SD 0006 (SD-06) is a MAPK p38 alpha inhibitor with an IC50 of 110 nM, indicated for the treatment of arthritis.

SD-066-4 is an orally active acyltransferase inhibitor that can be utilized in cancer research.